Pioneer of "One-Stop Solution" for the distribution of Pharmaceutical and Vaccines in China

Over a decade of effort since its establishment in 1995, NT Pharma (The Group), headquartered in Hong Kong, has developed into a corporation which possesses a full-range value-chain from research and development, production, sales and marketing to distribution of pharmaceutical and healthcare products. The Group is the only Hong Kong-funded integrated pharmaceutical enterprise capable in providing such this ‘one-stop solution’ in China.

The Group has established an operation management centre in Shanghai and four marketing subsidiaries in Shanghai, Beijing, Guangzhou and Hainan for the distribution of pharmaceutical products. Besides, it has established a trading subsidiary in the Wai Gaoqiao Free Trade Zone in Shanghai for pharmaceutical import and export business; a subsidiary in Zhang Jiang High Technology Park in Shanghai specializing in logistics; and a GMP-certified manufacturing plant and marketing company in Suzhou for the production and sales of the Group's own brand of pharmaceutical products, as well as a range of Active Pharmaceutical Ingredients (API) and raw materials.

Currently, the Group has 500 employees, of which over 100 with extensive, professional experience in pharmaceutical industry. The management team and the professional sales & marketing force are mainly come from renowned multinational pharmaceutical corporations. The diversity of our employees from different cultural backgrounds synthesizes visionary business acumens and enthusiastic attitudes, and becoming reliable human resources for rapid development of the Group.

In the early stage, the Group positioned itself as a provider of import and distribution services for multinational pharmaceutical corporations. Progressively, it successfully developed a nationwide pharmaceutical product distribution and logistics network. After strategic realignment between 2002 and 2005, the Group extended its scope of business vertically to R&D, production, as well as sales and marketing activities to end-users. Meanwhile, the Group has re-positioned itself as a provider of ‘one-stop solution’ for distribution of pharmaceutical and vaccine product of multinational brand, and as a R&D-based pharmaceutical corporation.  Recently, the core competitiveness as ‘one-stop solution’ provider is moving the Group to the right track:  In 2006, the Group achieved sales revenue of RMB 2.35 billion, with more than 1,400 items in the product portfolio.

With the ideals on integrity, innovation and people-oriented for the best interests of society in the mindset, the Group has also built long-term business relationships with leading multinational pharmaceutical corporations and well-known domestic enterprises. Major business partners include GlaxoSmithKline (GSK), Pfizer and Roche. Currently, the Group is the largest distributor of GSK vaccine products in China. The Group is also one of the largest distributors of Pfizer prescription drugs. Moreover, the Group possesses 164 licenses issued by the State Food and Drug Administration (“SFDA”) for the production of pharmaceutical products and API.  In particular, Shu Si®, the Group's own-branded product for the treatment of psychotic disorders, is well recognized in the pharmaceutical sector in China.

The Group will continue on launching innovative products and services to the market in the coming five years.  Our people will continue to utilize their innovations and market senses to establish a highly competitive business model, and make the Group a powerful driving force of the pharmaceutical and healthcare industry in China.